International Society of Microbiota

6th World Congress on

Targeting Microbiota

October 28-30, 2018 - Hotel Crowne Plaza, Porto, Portugal

Day 1 – Sunday, October 28

17h00 – 18h00   **Registration – Badges & Material Providing**

Day 2 – Monday, October 29

7h45   **Welcoming & registration of attendees**

8h50   **Introduction note by the President of ISM Targeting Microbiota 2018, Prof. Peter Konturek**

Session 1: Microbiota 2018: Recent Advances & Challenges

Chairs: Marvin Edeas, Maria Vehreschild

9h00   **Honor the lodgers? – Interaction between the built environment microbiome and the human microbiome (Skin & Gut)**
Markus Egert, Furtwangen University, Germany

9h25   **Impact of antibiotics and microbiota: recent scientific advances and perspectives**
Maria Vehreschild, University Hospital Frankfurt, Germany

9h50

10h15   **Exploring the role of gut dysbiosis in neuroinflammation and hypertension**
David Durgan, Baylor College of Medicine, USA

10h40   Coffee Break, Network, Exhibition & Poster Session

Chair: Julien Diana, Nicolas Cenac

11h20   **Link between microbiota & visceral pain: role of bioactive lipids**
Nicolas Cenac, Inserm, CHU Purpan, France

11h45   **Altered gut microbiota and endocannabinoid system tone in vitamin D deficiency-mediated chronic pain**
Francesca Guida, Università degli Studi della Campania "Luigi Vanvitelli", Italy

11h55   **Role of microbes in stem cells transplantation related complication**
Ernst Holler, University Hospital Regensburg, Germany

12h20   **Enteric microbiome markers as early predictors of clinical outcome in allogeneic hematopoietic stem cell transplant**
Nicasio Mancini, University Vita-Salute San Raffaele, Italy

12h30   **Metagenomic studies on gut microbial diversity in healthy controls and patients with *Entamoeba histolytica* infections from New Delhi**
Lakshmi Rani Iyer, Jawaharla Nehru University, New Delhi, India

12h40   Lunch Break, Network, Exhibition & Poster Session

Session 2: Strategies to manipulate microbiota & medicine of tomorrow

Chairs: Markus Egert, Peter Konturek

14h00   **Fecal Microbiota Transplant 2018: What's next?**
Peter Konturek, Teaching Hospital of the University of Jena, Germany

14h25   **Phage therapy strategy to modulate the child stunting microbiota**
Mohammadali Khan Mirzaei, McGill University, Canada

14h50   **Probiotic supplementation and associated infant gut microbiome and health: a cautionary retrospective clinical comparison**
Candice Quin, University of British Columbia, Canada

15h00   **Fermented milk by *Lactobacillus Delbrueckii* CIDCA 133 is able to ameliorate the chemotherapy-induced intestinal mucositis in Balb/c mice**
Mariana Martins Drumond, Universidade Federal de Minas Gerais, Brazil

15h10   **Microbiota "friendly" lipid nanoparticles to counteract the gastric infection burden**
Catarina Leal Seabra, University of Porto, Portugal

15h20   **Curative properties of three probiotics strains in a mice model of cow-milk allergy: impact on T-helper responses**
Nathalie Esber, University of Paris Descartes, France

15h30   **A new freeze-dried formulation to conserve stools over 12 months for fecal transplantation**
Julie Reygner, Université Paris Descartes - Faculté de Pharmacie, France

15h40   **Anaerobic cultivated human intestinal microbiota – ACHIM a way to restore intestinal microbiota functions in IBS patients**
Elizabeth Norin, Karolinska Institutet, Sweden

15h50   **IL-33 induced by dysbiosis in vaginal microbiota contributes to impaired antiviral immunity against herpes simples virus infection to vaginal mucosa**
Heung Kyu Lee, Korea Advanced Institute of Science and Technology, Korea

16h00   **Bacterial quorum sensing molecules manipulate host satiety pathway**
Paola Brun, University of Padova, Italy

<div align="center">

16h10   Coffee Break, Network, Exhibition & Poster Session

Session 3: Microbiota sequencing, big data interpretation, and artificial intelligence: myth or reality?

Chair: Yasubumi Sakakibara

</div>

16h50   **Microbiota sequencing, big data interpretation, and artificial intelligence: myth or reality?**
The aim of this discussion is to connect all the key actors involved in microbiota assessment and analysis: mathematician, computer scientists, bioinformatician, clinician, academics and industrials in order to initiate the discussion about sequencing, big data generating and how to integrate artificial intelligence into microbiota analysis interpretation.

       Introduction – Metagenome analysis and bioinformatics method for metagenome assembly: recent advances and perspectives
Yasubumi Sakakibara, Keio University, Japan

       Development of meta-transcriptome analysis method and its application to meta-transcriptome map of common marmoset
Mika Uehara, Keio University, Japan

17h15   **A preliminary study on bioinformatics probiotic database for microbiota**
Melike Yilmaz, Izmir Institute of Technology, Turkey

17h25   **Electron-microscopic analysis of skin bacterial microbiota in patients with atopic dermatitis and in healthy human hosts**
Oksaba V. Rybalchenko, St Petersburg State University, Russian Federation

17h35   **Improving the accuracy and reproducibility of microbiome measurements across labs**
Thomas Kuri, Zymo Research Europe GmbH, Freiburg, Germany

17h45   **A higher standard for microbiome studies: best practices from sampling to analysis**
Evgueni Doukhanine, DNA Genotek, Canada

18h05   **Genomics solutions that enhance and accelerate microbiota analysis**
Mette K. Lund, Eurofins Genomics, Denmark

18h15   **Assessing gut microbiota-host crosstalk: development of a standardized and quantitative targeted metabolomics**
Carlos Malpica, MLP Vision Biotech SL, Spain

18h25   ***Identification of bacterial taxa with a potential role in Parkinson's disease using illumine MiSeq and Ion Torrent PGM next generation sequencing***
Severin Weis, Furtwangen University, Germany

18h35   **Discussion**
18h45   **End of the day**
20h30   **Targeting Microbiota Dinner - The dinner will be at the InterContinental Porto -** Praça da Liberdade, 25, 4000-322 Porto, Portugal

International Society of Microbiota

Day 3 – Tuesday, October 30

8h25 **Opening of the second day**

Session 4: Strategic role of metabolites and mediators on the microbiota-host cross-talk

Chair: Knut Rudi

8h30 **Microbiota and mitochondria inter-talk in hemodialysis patients: a pilot study**
Marvin Edeas, Université Paris Descartes, Institut Cochin, France

8h55 **Crosstalk between gut microbiota, innate immune cells and endocrine cells in the pancreas regulates autoimmune diabetes**
Julien Diana, Institut National de la Santé et de la Recherche Médicale (INSERM), France

9h20 **MAIT cells (Mucosal-Associated Invariant T cells) in liver disease and antibacterial response**
Antonio Riva, Institute of Hepatology London, Foundation for Liver Research, United Kingdom

9h45 **The effect of gut bacterial metabolites on cardiovascular risk**
Marcin Ufnal, Medical University of Warsaw, Poland

10h10 **The triple interaction diet-microbiome-epigenome: a novel approach to type 1 diabetes**
Annalisa Terranegra, Sidra Medicine, Qatar

10h20 **Examining the relationship between maternal body size, gestational glucose tolerance, mode of delivery and ethnicity on human milk microbiota at 3 months post-partum**
Lauren Lemay-Nedjelski, University of Toronto, Canada

10h30 Coffee Break, Network, Exhibition & Poster Session

Chair: Ernst Holler

11h15 **Targeted gut microbiota and short chain fatty acid profile among term and preterm infants**
Jan Mazela, Poznan University of Medical Sciences, Poland

11h40 **Psycho neuro immunology and gut microbes**
Paul Forsythe, McMaster University, Canada

12h05 **Using germfree animal models to prove the role of the gut microbiota in liver diseases**
Philippe Gérard, INRA, France

12h30 **Gut microbiota from infant with cow's milk allergy leads to atopic orientation in a murine model of CMA**
Aurélie Mauras, University of Paris Descartes, France

12h40 Lunch Break, Network, Exhibition & Poster Session

Chair: Jan Mazela, Carole Nicco

13h45 **Recent advances on the relation between the microbiome-gut-brain axis and the neurodegenerative diseases**
Maria Cecilia Giron, University of Padova, Italy

14h10 **Individual differences in the microbiome and metabolome during circadian misalignment and sleep restriction: associations with the ability to maintain wakefulness**
Kenneth Wright, University of Colorado Boulder, USA

14h35 **Sepsis and microbiota: obstacles, recent advances and strategies**
Natalia Beloborodova, Negovsky Research Institute of General Reanimatology, Russia

15h00 **Gut dysbiosis and altered barrier function precedes the appearance of metabolic syndrome in a rat model of maternal food-restriction**
Paula Martínez-Oca, University Complutense of Madrid, Spain

15h10 **Fecal microbiota transplantation in the intestinal decolonization of carbapenemase-producing *Klebsiella pneumonia*: new therapeutic application?**
João Carlos Silva, Centro Hospitalar Vila Nova de Gaia Espinho, Portugal

15h20   **Current and new approaches for measuring gut-blood barrier permeability**
Kinga Jaworska, Medical University of Warsaw, Poland

15h30   Coffee Break, Network, Exhibition & Poster Session

Chairs: Paul Forsyth

16h05   **Interventional strategies binding the human blood microbiota with the states of health, latent and active tuberculosis**
Stefan Panaiotov, National Center of Infectious and Parasitic Diseases, Bulgaria

16h15   **Delayed liver regeneration in germ-free mice is normalized following colonization with conventional mouse microbiota**
Antony M. Wheatley, National University of Ireland, Ireland

16h25   **Bile acids, MAIT cell activity and inflammatory parameters and the link to weight in 15 years old children**
Gunda Herberth, Helmholtz Center for Environmental Research Leipzig, Germany

16h35   **Akkermansia Muciniphila ameliorates inflammatory bowel disease via improvement of gut tight junction and epithelial cell ER stress**
Qiaozhu Su, Queen's University Belfast, United Kingdom

16h45   **Is skeletal muscle remodeling associated with gut microbiota signature?**
Maxence Jollet, University Montpellier, INRA, France

16h55   **Evaluation of the effect of the oral consumption of capsules containing *Lactobacillus Paracasei* LPC-S01 on the vaginal microbiota of healthy adult women: A randozimed, placebo-controlled, double-blind, crossover pilot trial**
Simone Guglielmo, Università degli Studi di Milano, Italy

17h05   **Intestinal Microbiota as a risk for antimicrobial resistance spread – health and ecological threat**
Helena Neto Ferreira, University of Porto, Portugal

17h15   **General discussion & Concluding remarks**
Among of questions which will be discussed:
- Microbiota 2018: Marketing, Claims & Regulations - Bridging the gap between Marketing Strategy and Science
- Microbiota & Medecine of tomorrow: Can we speculate?

Targeting Microbiota 2018 Awards

17h45   **End of Targeting Microbiota 2018**